Ozempic vs Wegovy: One Ingredient, Two Different Labels

    Short answer

    Ozempic and Wegovy both contain semaglutide from Novo Nordisk, but they are separate products with separate FDA labels. Ozempic is approved for adults with type 2 diabetes. Wegovy is approved for long-term weight reduction, heart risk reduction and, as an injection, MASH. Their dose steps, forms and side-effect figures differ.

    Ozempic and Wegovy are both semaglutide medicines made by Novo Nordisk. Ozempic is approved for adults with type 2 diabetes, while Wegovy is approved for long-term weight reduction and to lower heart risk in people with heart disease and obesity or overweight. Below, the two FDA labels sit side by side: the Ozempic injection label (revised 05/2026), the Ozempic tablets label (revised 01/2026) and the Wegovy label (revised 06/2026). Nothing here picks a winner, because that choice belongs with you and your prescriber.

    The Short Answer

    Same Active Ingredient, Same Maker

    Both medicines contain semaglutide, a GLP-1 receptor agonist, and both come from Novo Nordisk. Pep AI is not affiliated with Novo Nordisk, and every fact here comes from the public FDA labels.

    Different Approved Uses

    Ozempic is approved to improve blood sugar in adults with type 2 diabetes and to lower certain heart and kidney risks in that group. Wegovy is approved for weight reduction, for heart risk reduction and, as an injection, for a liver condition called MASH.

    Different Dose Ladders

    Both injection labels start at 0.25 mg once a week and step up in 4-week stages. The Ozempic ladder tops out at 2 mg, while the Wegovy injection label lists 2.4 mg as its recommended maintenance step for adult weight reduction.

    Both Brands Now Have a Daily Tablet

    Each brand also has a once-daily semaglutide tablet with its own steps. Wegovy tablets share the Wegovy label, while Ozempic tablets are on a separate label shared with Rybelsus, revised January 2026.

    Ozempic and Wegovy at a Glance

    One row per label fact, from the Ozempic, Ozempic tablets and Wegovy prescribing information.

    OzempicWegovy
    IngredientSemaglutideSemaglutide
    MakerNovo NordiskNovo Nordisk
    Approved usesType 2 diabetes in adults; heart and kidney risk reduction in some of those adultsWeight reduction (adults; children 12+ for the injection); heart risk reduction; MASH (injection)
    FormsWeekly injection; daily tablet on a separate labelWeekly injection; daily tablet on the same label
    Do not use withPersonal or family history of MTC, or MEN 2Personal or family history of MTC, or MEN 2

    Approved Uses in Full

    Ozempic is approved to improve blood sugar control in adults with type 2 diabetes. In those adults, its label also covers lowering major heart event risk when heart disease is present and lowering kidney decline risk when chronic kidney disease is present.

    Wegovy injection is approved for weight reduction in adults and in children 12 and older with obesity, plus adults with overweight and a weight-related condition. It is also approved to lower major heart event risk in adults with heart disease and obesity or overweight, and for MASH with moderate to advanced liver scarring.

    Forms and How Often You Take Them

    Ozempic injection comes in a multi-dose pen or a single-dose prefilled syringe, taken once a week at any time of day, with or without meals. Wegovy injection comes in single-dose pens, single-dose syringes or a multi-dose FlexTouch pen, also once a week.

    Wegovy tablets and Ozempic tablets are both taken once a day on an empty stomach in the morning with up to 4 ounces of water. Both labels say to wait at least 30 minutes before eating, drinking or taking other oral medicines.

    Who Should Not Use Either One

    Both labels say not to use the medicine with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both also rule out anyone with a known allergy to semaglutide or the product's other ingredients.

    Taking Them Together

    The Wegovy label says using it with other semaglutide products or any other GLP-1 receptor agonist is not recommended. Since Ozempic is also semaglutide, the two are not meant to be combined.

    Dose Steps Listed on Each Label

    Quoted from the FDA labels so the numbers make sense. These are each label's own schedule, not a recommendation or a plan for you.

    Ozempic Steps

    The Ozempic label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly. If more blood sugar control is needed, it lists 1 mg and then 2 mg, each after at least 4 weeks on the step before.

    Wegovy Injection Steps

    The Wegovy label lists 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16. For adult weight reduction the maintenance step is 1.7 mg or 2.4 mg, with 2.4 mg recommended and 7.2 mg listed as a maximum for some adults.

    Tablet Steps on Each Label

    Wegovy tablets start at 1.5 mg once daily for 30 days, then 4 mg and 9 mg for 30 days each, with 25 mg once daily from day 91. Ozempic tablets start at 1.5 mg once daily for 30 days, then 4 mg, with 9 mg listed from day 61 if more blood sugar control is needed.

    Why the Steps Are Slow

    Both labels step up gradually to lower the chance of stomach side effects. Your prescriber sets your steps, and a milligram on one label is not a guide to the other.

    Common Side Effects on Each Label

    Real label numbers, each read against its own placebo. The Ozempic figures are from type 2 diabetes trials at the two doses studied; the Wegovy figures are from weight-reduction trials of 2.4 mg.

    Side effectOzempic (diabetes trials)Wegovy 2.4 mg (weight trials)
    Nausea15.8% and 20.3% vs 6.1% placebo44% vs 16% placebo
    Diarrhea8.5% and 8.8% vs 1.9% placebo30% vs 16% placebo
    Vomiting5% and 9.2% vs 2.3% placebo24% vs 6% placebo
    Constipation5% and 3.1% vs 1.5% placebo24% vs 11% placebo
    Stomach pain7.3% and 5.7% vs 4.6% placebo20% vs 10% placebo

    Stomach Effects Lead Both Lists

    Nausea, vomiting, diarrhea, stomach pain and constipation are the most common side effects on both labels. The Wegovy label also lists headache, fatigue, indigestion, dizziness, bloating, burping, gas, reflux and hair loss among its common effects.

    Why the Numbers Are Not a Fair Head-to-Head

    The two sets of figures come from different trials, different doses and different groups of people. They show what each label reports, not how the same person would feel on each one.

    Full Breakdowns for Each Brand

    The GLP-1 side effects guide covers the Wegovy label's full table and the warning signs to act on, and GLP-1 nausea covers the most common one in detail.

    The Boxed Warning and Other Shared Risks

    Because the ingredient is the same, the serious warnings largely overlap.

    Boxed Warning: Thyroid C-Cell Tumors

    Both labels carry a boxed warning because semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it does this in people. Neither should be used with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2. Report a lump or swelling in the neck, trouble swallowing, hoarseness or shortness of breath.

    Pancreatitis and Gallbladder Problems

    Both labels list acute pancreatitis and acute gallbladder disease. Severe stomach pain that will not go away, sometimes spreading to the back, needs prompt medical attention.

    Fluid Loss and the Kidneys

    Severe vomiting or diarrhea can lead to dehydration, which both labels link with acute kidney injury. Neither medicine is recommended for people with severe gastroparesis.

    Low Blood Sugar, Eye Changes and Procedures

    Low blood sugar is more likely when either medicine is used with insulin or a sulfonylurea. Both labels also mention diabetic eye complications and ask you to tell your care team about any planned surgery that uses anesthesia or deep sedation.

    Track Either Medicine in Pep AI

    Once a prescriber has chosen, the daily work starts.

    Log a Shot or a Daily Tablet

    Pep AI logs an Ozempic or Wegovy shot in a couple of taps, or a daily tablet with its own schedule. Step-ups go on the same history, so you always know which step you are on. See the Ozempic tracker and the Wegovy tracker.

    Reminders on Your Lock Screen

    Pep AI sends shot-day reminders that show on your Lock Screen, and a daily tablet gets its own schedule. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.

    Symptoms, Day by Day

    Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can check a rough patch against when your step changed.

    Weight and Photos on One Trend

    Pep AI keeps your weight trend and progress photos in one place, and can pull weight from Apple Health on iPhone or Health Connect on Android. The trend shows the weeks, not just the day.

    Questions to Bring to Your Prescriber

    The right medicine is a decision for you and your prescriber. These questions help the visit.

    Which Label Matches Your Diagnosis

    Ask which approved use applies to you, since the two labels cover different conditions. Your prescriber decides which medicine, if either, is right.

    How Your Steps Will Be Set

    Ask how and when your dose will change, and what to do if a step feels hard. Your label and your prescriber are the only sources for dose instructions.

    Other Medicines You Take

    Both medicines slow stomach emptying, which can change how some pills are absorbed. Mention every medicine you take, especially insulin or a sulfonylurea.

    A Report Ready Before You Arrive

    Pep AI turns your doses, injection sites, weight and daily meal totals into a PDF report you can share with your prescriber. Share it from your phone so the visit starts with facts.

    Key takeaways

    • Ozempic and Wegovy both contain semaglutide from Novo Nordisk, on separate FDA labels.
    • Ozempic is for type 2 diabetes; Wegovy covers weight reduction, heart risk reduction and, as an injection, MASH.
    • Both injection labels start at 0.25 mg weekly; Ozempic tops out at 2 mg, and Wegovy recommends 2.4 mg for adult maintenance.
    • Stomach effects lead both labels, and both carry the thyroid C-cell tumor boxed warning.
    • They are not taken together, and any change between them is your prescriber's decision.

    Whatever your prescriber decides, keep the record.

    Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Ozempic (semaglutide) injection prescribing information, Novo Nordisk / FDA (revised 05/2026)
    2. Rybelsus and Ozempic (semaglutide) tablets prescribing information, Novo Nordisk / FDA (revised 01/2026)
    3. Wegovy (semaglutide) prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)

    This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026